NBC Securities Inc. Raises Stake in AbCellera Biologics Inc. (NASDAQ:ABCL)

NBC Securities Inc. lifted its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 56.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,420 shares of the company’s stock after purchasing an additional 4,100 shares during the period. NBC Securities Inc.’s holdings in AbCellera Biologics were worth $29,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ABCL. Evergreen Capital Management LLC acquired a new stake in AbCellera Biologics in the second quarter valued at $32,000. B. Riley Wealth Advisors Inc. grew its stake in AbCellera Biologics by 104.8% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company’s stock valued at $64,000 after acquiring an additional 11,000 shares during the last quarter. Seelaus Asset Management LLC purchased a new position in AbCellera Biologics during the 1st quarter valued at about $68,000. Creative Planning acquired a new position in AbCellera Biologics during the third quarter worth about $93,000. Finally, XTX Topco Ltd purchased a new stake in shares of AbCellera Biologics in the second quarter valued at about $99,000. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Price Performance

NASDAQ:ABCL opened at $2.77 on Tuesday. AbCellera Biologics Inc. has a 1-year low of $2.34 and a 1-year high of $6.05. The firm has a 50 day simple moving average of $2.59 and a 200-day simple moving average of $3.16. The firm has a market cap of $814.53 million, a PE ratio of -5.33 and a beta of 0.38.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $10.12 million. AbCellera Biologics had a negative return on equity of 13.40% and a negative net margin of 463.77%. The business’s revenue for the quarter was down 27.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.11) EPS. As a group, sell-side analysts expect that AbCellera Biologics Inc. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ABCL shares. Benchmark downgraded AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. KeyCorp reissued an “overweight” rating and issued a $5.00 price target (down from $7.00) on shares of AbCellera Biologics in a report on Thursday, July 11th.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.